阿卡替尼单药治疗复发/难治性慢性淋巴细胞白血病的2期更新结果
该1b/2期研究纳入134例复发/难治性CLL/SLL患者,接受阿卡替尼100 mg每日两次,中位治疗41个月;总缓解率94%,估计45个月PFS为62%,长期安全性可控,支持进一步研究。
要点
- 阿卡替尼100 mg每日两次在复发/难治CLL/SLL中总缓解率达94%。
- 估计45个月无进展生存率为62%(95%CI 51%–71%)。
- 多数不良事件为轻中度,≥3级常见中性粒细胞减少14%、肺炎11%。
核心结论
- 阿卡替尼单药在复发/难治性CLL/SLL中具有持久疗效和长期安全性,支持进一步研究。
研究设计与样本
- 1b/2期研究纳入134例复发/难治性CLL或SLL患者,中位年龄66岁,中位既往治疗2线。
- 患者接受阿卡替尼100 mg每日两次,中位治疗41个月(范围0.2–58个月)。
主要发现
- 总缓解率(含伴淋巴细胞增多的部分缓解)为94%,且不受del(11)(q22.3)、del(17)(p13.1)、复杂核型或IGHV突变状态影响。
- 中位缓解持续时间和无进展生存期未达到,估计45个月PFS为62%(95%CI 51%–71%)。
- 最常见不良事件为腹泻52%和头痛51%;≥3级不良事件(≥5%)包括中性粒细胞减少14%、肺炎11%、高血压7%、贫血7%、腹泻5%。
- 房颤和重大出血(所有级别)分别发生于7%和5%的患者;56%患者仍在治疗,停药主要原因为疾病进展21%和不良事件11%。
- 复发时9例患者中6例(67%)检测到BTK突变。
关键数值与推荐
- 阿卡替尼给药方案为100 mg每日两次口服。
- 稳态中位BTK占用率为97%。
临床怎么用
- 阿卡替尼100 mg每日两次可作为复发/难治性CLL/SLL的有效口服单药治疗选择。
- 治疗期间需监测中性粒细胞减少、肺炎、高血压、贫血、房颤和重大出血等不良事件。
局限性
- 本研究为1b/2期单臂研究,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Acalabrutinib is an oral, highly selective BTK inhibitor that allows for twice-daily dosing due to its selectivity. In this phase 1b/2 study, 134 patients with relapsed/refractory CLL or SLL (median age, 66 years [range, 42-85 years]; median prior therapies, 2 [range, 1-13]) received acalabrutinib 100 mg twice daily for a median of 41 months (range, 0.2-58 months). Median trough BTK occupancy at steady state was 97%. Most adverse events (AEs) were mild or moderate, and were most commonly diarrhea (52%) and headache (51%). Grade ≥3 AEs (occurring in ≥5% of patients) were neutropenia (14%), pneumonia (11%), hypertension (7%), anemia (7%), and diarrhea (5%). Atrial fibrillation and major bleeding AEs (all grades) occurred in 7% and 5% of patients, respectively. Most patients (56%) remain on treatment; the primary reasons for discontinuation were progressive disease (21%) and AEs (11%). The overall response rate, including partial response with lymphocytosis, with acalabrutinib was 94%; responses were similar regardless of genomic features (presence of del(11)(q22.3), del(17)(p13.1), complex karyotype, or immunoglobulin variable region heavy chain mutation status). Median duration of response and progression-free survival (PFS) have not been reached; the estimated 45-month PFS was 62% (95% confidence interval, 51% to 71%). BTK mutation was detected in 6 of 9 patients (67%) at relapse. This updated and expanded study confirms the efficacy, durability of response, and long-term safety of acalabrutinib, justifying its further investigation in previously untreated and treated patients with CLL/SLL. This trial was registered at www.clinicaltrials.gov as #NCT02029443.
引用
- Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020. PMID: 31876911. doi:10.1182/blood.2018884940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。